These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33581999)

  • 1. Recurrent hyperhemolytic transfusion reaction in myelodysplastic syndrome- A case based approach.
    Augustine M; Murugesan M; Nair CK; Raghavan V; Nayanar SK
    Transfus Apher Sci; 2021 Jun; 60(3):103073. PubMed ID: 33581999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhemolytic Transfusion Reaction in Non-Hemoglobinopathy Patients and Terminal Complement Pathway Activation: Case Series and Review of the Literature.
    Cid J; Fernández J; Palomo M; Blasco M; Bailó N; Diaz-Ricart M; Lozano M
    Transfus Med Rev; 2020 Jul; 34(3):172-177. PubMed ID: 32703665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS
    Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes.
    Moncharmont P; Quittançon E; Barday G; Benamara A;
    Vox Sang; 2019 May; 114(4):349-354. PubMed ID: 30818416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperhemolytic Syndrome Complicating a Delayed Hemolytic Transfusion Reaction due to anti-P1 Alloimmunization, in a Pregnant Woman with HbO-Arab/β-Thalassemia.
    Bezirgiannidou Z; Christoforidou A; Kontekaki E; Anastasiadis AG; Papamichos SI; Menexidou H; Margaritis D; Martinis G; Mantadakis E
    Mediterr J Hematol Infect Dis; 2016; 8(1):e2016053. PubMed ID: 27872733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications.
    Gupta P; LeRoy SC; Luikart SD; Bateman A; Morrison VA
    Leuk Res; 1999 Oct; 23(10):953-9. PubMed ID: 10573142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced hemolysis: cefotetan-dependent hemolytic anemia mimicking an acute intravascular immune transfusion reaction.
    Stroncek D; Procter JL; Johnson J
    Am J Hematol; 2000 May; 64(1):67-70. PubMed ID: 10815791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
    Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhemolysis in sickle cell disease.
    Aragona E; Kelly MJ
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):e54-6. PubMed ID: 23619113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
    Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP
    Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review.
    Win N; Sinha S; Lee E; Mills W
    Transfus Med Rev; 2010 Jan; 24(1):64-7. PubMed ID: 19962576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel method for the laboratory workup of anaphylactic transfusion reactions in haptoglobin-deficient patients.
    Thoren KL; Avecilla ST; Klimek V; Goss C
    Transfusion; 2020 Apr; 60(4):682-687. PubMed ID: 31975382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse impact of hyperferritinemia and transfusion dependency on treatment success in myelodysplastic syndrome.
    Cakar MK; Yegin ZA; Baysal NA; Altındal S; Pamukçuoğlu M; Celik B; Yenicesu I
    Transfus Apher Sci; 2013 Jun; 48(3):397-401. PubMed ID: 23619324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of premedication and other factors on the occurrence of acute transfusion reactions in dogs.
    Bruce JA; Kriese-Anderson L; Bruce AM; Pittman JR
    J Vet Emerg Crit Care (San Antonio); 2015; 25(5):620-30. PubMed ID: 26109490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of complications after blood components' transfusions.
    Timler D; Klepaczka J; Kasielska-Trojan A; Bogusiak K
    Pol Przegl Chir; 2015 Apr; 87(4):166-73. PubMed ID: 26146115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
    Leisch M; Weiss L; Lindlbauer N; Jungbauer C; Egle A; Rohde E; Greil R; Grabmer C; Pleyer L
    Leuk Res; 2017 Aug; 59():12-19. PubMed ID: 28535394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-N and anti-Do
    Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
    Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease.
    Reyes MA; Illoh OC
    Immunohematology; 2008; 24(2):45-51. PubMed ID: 19852130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion.
    Uhlmann EJ; Shenoy S; Goodnough LT
    Transfusion; 2014 Feb; 54(2):384-8. PubMed ID: 23692505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.